

Listing of Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1. (Canceled)

Claim 2. (Canceled)

Claim 3. (Canceled)

Claim 4. (Currently Amended) The oral dosage form according to claim 318 wherein said cellulose ether is hydroxypropyl methyl cellulose.

Claim 5. (Canceled)

Claim 6. (Currently Amended) The oral dosage form according to claim 318 wherein said cellulose ether is ethyl cellulose.

Claim 7. (Canceled)

Claim 8. (Currently Amended) The oral dosage form according to claim 318 comprising a polymethacrylate which is trimethylammonium methacrylate.

Claim 9. (Currently Amended) The oral dosage form according to claim 318 wherein said filler is microcrystalline cellulose.

Claim 10. (Currently Amended) The oral dosage form according to claim 418 wherein said dosage form has an 80% or greater release of the oxcarbazepine dose within 1 hour indicated in standard in vitro dissolution tests at 37 degrees Celsius in water using

sodium dodecyl sulphate as a solubilizing agent at a concentration of 1% for a 600 mg dosage form.

Claim 11. (Currently Amended) The oral dosage form according to claim 4-18 wherein said dosage form releases oxcarbazepine at a constant release rate for 4 hours or more as indicated in standard in vitro dissolution tests at 37 degrees Celsius in water using sodium dodecyl sulphate as a solubilizing agent at a concentration of 1% for a 600 mg dosage form.

Claim 12. (previously presented) The oral dosage form according to claim 11 wherein said dosage form releases about 80% of oxcarbazepine within 8 hours.

Claim 13. (Canceled)

Claim 14. (Canceled)

Claim 15. (Canceled)

Claim 16. (Currently Amended) A method for the treatment of epilepsy, comprising orally administering to a patient in need of oxcarbazepine an oral dosage form of claim 4-18.

Claim 17. (Currently Amended) A method of reducing the variability of bioavailability of cyclosporin A for patients during oxcarbazepine therapy, said method comprising orally administering to a patient in need of oxcarbazepine therapy an oral dosage form of claim 4-18.

Claim 18. (New) An oral dosage form, comprising: a tablet core and a coating wherein the core comprises oxcarbazepine, optionally, a filler, and at least one further excipient selected from the group comprising cellulose ethers, carboxyvinyl polymer of acrylic

acid cross linked with alkyl ethers of sucrose, carboxyvinyl polymer of acrylic acid cross linked with pentaerythritol, and polymethacrylates, wherein the weight ratio of said excipient to oxcarbazepine is from about 1:10 to about 1:20, wherein when administered once a day to a patient, is released to produce constant MHD plasma levels over 24 hours in said patient.